Key insights
- Amarin will present additional data from its REDUCE-IT trial at a cardiology meeting, focusing on high-risk cardiovascular patients. Analysts predict profitability for Amarin this year, and InvestingPro suggests the stock is undervalued. The company's drug VASCEPA/VAZKEPA is approved in multiple countries. This news may positively influence investor sentiment towards Amarin and the broader pharmaceutical sector, but the overall impact on the US equity market is limited.
DUBLIN and BRIDGEWATER, N.J. - Amarin Corporation (NASDAQ:AMRN) announced that additional patient subgroup analysis from its REDUCE-IT trial and mechanistic data will be presented at the American College of Cardiology’s Annual Scientific Session & Expo, scheduled for March 28-30 in New Orleans.
The presentations will include an oral presentation on the efficacy of icosapent ethyl among patients at extreme cardiovascular risk, available March 29 at 12:30 p.m. CST. A poster presentation examining rates of lipoprotein(a) oxidation and inhibition by eicosapentaenoic acid will be available March 28 at 11:00 a.m. CST.Investor interest in Amarin has surged, with shares delivering an 85% return over the past year. According to InvestingPro Tips, analysts predict the company will be profitable this year after recent losses.
The REDUCE-IT trial was a global cardiovascular outcomes study that followed 8,179 patients at over 400 clinical sites in 11 countries over seven years, completing in 2018. The study evaluated adult patients with LDL-C controlled between 41-100 mg/dL by statin therapy and elevated triglycerides between 135-499 mg/dL.
Amarin’s product VASCEPA was approved by the FDA in January 2020 for treatment of high-risk patients with persistent cardiovascular risk despite statin therapy. The drug has been prescribed more than 25 million times since its initial 2013 launch. VASCEPA is approved and sold in multiple countries including the United States, Canada, China, and Australia. In Europe, the product is marketed under the brand name VAZKEPA.
InvestingPro analysis suggests the stock is currently undervalued, placing it among opportunities on the platform’s most undervalued stocks list. Investors seeking deeper insights can access a comprehensive Pro Research Report covering AMRN and 1,400+ other US equities.The information is based on a press release statement from the company.
In other recent news, Amarin Corporation reported its earnings for the fourth quarter of 2025, revealing a 21% decline in total net revenue, which amounted to $49.2 million. Despite this decrease, the company emphasized significant strategic progress during their earnings call. The revenue figures reflect a year-over-year comparison, indicating challenges in maintaining previous levels. Analysts and investors were particularly attentive to these developments as they assess the company’s financial health. The earnings call did not disclose any mergers or acquisitions, focusing instead on internal strategies. There were no analyst upgrades or downgrades reported in the latest updates. These developments are part of a broader narrative investors are monitoring closely.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.